Jul. 2 at 4:13 PM
$ATAI $GHRS 🔥 ATAI vs GHRS (GH Research) – Why ATAI Is the Real 5-MeO-DMT Leader 🔥
1. Trial Design
ATAI just dropped Phase 2b data – randomized, controlled, blinded, 193 patients across 6 countries (incl. U.S.).
GHRS did a small Phase 2a, open-label, ~8–12 patients, mostly Europe. No placebo. No control. Huge difference in quality.
2. Results – Efficacy
ATAI’s 8mg dose:
🔹 Day 8: -11.1 MADRS
🔹 Day 29: -12.1 MADRS (p=0.0025)
🔹 Week 8: -10.8 MADRS
GHRS had short-term gains, but no long-term data or control group.
3. Safety & Delivery
ATAI: intranasal spray, 2-hour clinic fit, 99% mild/moderate AEs, no serious events.
GHRS: inhaled format, less practical for clinical rollout. Safety looks fine but less clarity.
4. Commercial Advantage
ATAI has cash (
$150M+), is prepping Phase 3, and targets the Spravato 2-hour clinic model.
GHRS had early hype, but slowed down. ATAI is built for scale and FDA alignment.
